Edit Symbol List

Symbol List Views

• FlashQuotes
• InfoQuotes

Stock Details

• Real-Time Quotes
• Summary Quotes
• After Hour Quotes
• Pre-market Quotes
• Historical Quotes
• Options Chain

CHARTS

• Basic Charts
• Interactive Charts
• After Hour Charts
• Pre-market Charts

COMPANY NEWS

• Company Headlines
• Press Releases
• TheStreet.com
• Fool.com

STOCK ANALYSIS

• Analyst Research
• Guru Analysis
• Stock Report
• View Competitors
• Stock Consultant
• Stock Comparison

FUNDAMENTALS

• Annual Report
• Financials
• Revenue/EPS
• Real-Time SEC
• Short Interest

HOLDINGS

• Holdings Summary
  (Ownership)
• Detailed Institutional
  Holdings
• Insider Form 4

MITI: Stock Quote & Summary Data

$ 6.90 0.23 3.23%
Nov. 20, 2009 Market Closed
Update Quotes: . Updates every 7 Seconds.

MITI | Micromet, Inc. | Common Stock | Market : NASDAQ-GM

News

Price Charts

Company Financials

Hoovers Profile

Last Sale	$ 6.90
Change Net / %	0.23 3.23%
Best Bid / Ask	N/A / N/A
1y Target Est:	N/A
Today's High / Low	$ 7.20 /  $ 6.62
Share Volume	299,545
50 Day Avg. Daily Volume	338,057
Previous Close	$ 7.13
52 Wk High / Low	$ 8.48 / $ 2.25
Shares Outstanding	68,687,000
Market Value	$ 473,940,300
Annualized Dividend	N/A
Ex Dividend Date	N/A
Dividend Payment Date	N/A
Current Yield	N/A
Beta	2.58
NASDAQ Official Open Price:	$ 7.08
Date of NASDAQ Official Open Price:	Nov. 20, 2009
NASDAQ Official Close Price:	$ 6.90
Date of NASDAQ Official Close Price:	Nov. 20, 2009

Intraday Chart

5d | 1m | 6m | 12m | More Charting

 Company Description (as filed with the SEC)

We are a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of our antibodies are currently in clinical trials, while the remainder of our product pipeline is in preclinical development. MT103, also known as MEDI-538, the most advanced antibody in our product pipeline developed using our BiTE® antibody technology platform, is being evaluated in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin’s lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient’s own cytotoxic T cells, considered the most powerful “killer cells” of the human immune system, to eliminate cancer cells. We are developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc.  ... More ...